Your session is about to expire
← Back to Search
Amivantamab + Lazertinib for Lung Cancer
Study Summary
This trial is testing two drugs, amivantamab and lazertinib, to see if they are effective against metastatic NSCLC with an EGFR mutation. Both drugs work by targeting cancer cells with an EGFR mutation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Patients with leptomeningeal (LM) disease with or without parenchymal brain metastases
- Group 2: Patients with parenchymal brain metastases
Frequently Asked Questions
What is the aggregate number of participants involved in this trial?
"That is accurate. Clinicaltrials.gov confirms that the medical trial was initially posted on September 30th 2021 and has been actively recruiting since then. 40 participants are required from 7 different sites."
Has this trial pioneered a new methodology?
"Currently, there are 13 Lazertinib trials that span 37 countries and 135 cities. The beginning of this research journey can be traced back to 2016 when Janssen Research & Development, LLC conducted a Phase 1 study which involved 780 participants. Since then, 6 further medical experiments have been concluded."
Are recruiting efforts still underway for the research trial?
"Clinicaltrials.gov confirms that this clinical trial is actively recruiting new participants, having first been posted on September 30th 2021 and last amended on August 1st 2022."
Are there any Canadian facilities actively participating in this research?
"Currently, 7 sites are enrolling for this trial; these locations include Montvale, Harrison and Uniondale. To reduce travel times, it is beneficial to choose the medical centre closest to you when signing up for participation."
For which medical conditions is Lazertinib most commonly utilized?
"Lazertinib is a therapeutic option for those who have previously received platinum based therapy, present with exons, or suffer from malignant neoplasms."
To what extent does Lazertinib guarantee a secure treatment for patients?
"Lazertinib's safety is rated a 2, as it has undergone Phase 2 trials which indicate its security but lack of data regarding efficacy."
Can you provide insight into other research concerning Lazertinib?
"In 2016, Lazertinib was initially examined at Asan Medical Center. There are now 6 finished clinical trials and a further 13 active ones; many of which have been launched by Montvale in New york."
Share this study with friends
Copy Link
Messenger